il13ra2 antibody  (Beyotime)

Journal: Materials Today Bio

Article Title: Development and evaluation of IL13RA2 targeted drug delivery system based on glioblastoma homing peptide A2b11

doi: 10.1016/j.mtbio.2026.102823

Figure Lengend Snippet: Analysis of IL13RA2's Research Value in Gliomas Using Public Databases ( a ) Differential expression of IL13RA2 across various tumors and their corresponding normal tissues, where red indicates high IL13RA2 expression in the disease and green indicates low IL13RA2 expression in the disease. Additionally, the full names of each disease depicted in the figure are listed in . ( b ) Differential expression of IL13RA2 in low-grade gliomas (LGG, T (tumor tissue) = 518, N (normal tissue) = 207), GBM (T (tumor tissue) = 163, N (normal tissue) = 207), (statistical analysis by Wilcoxon test). ( c ) Expression differences of IL13RA2 among gliomas of different grades ( ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 ). ( d ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-325 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.94 , CNS WHO Grade 3: P = 0.013 , Grade 4: P = 0.0035 ). ( e ) Kaplan-Meier survival curves comparing high- and low-IL13RA2 expression groups across glioma grades (data from CGGA-693 databases; survival analysis by log-rank test; CNS WHO Grade 2: P = 0.55 , CNS WHO Grade 3: P = 0.0034 , Grade 4: P = 0.019 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Subsequently, 5′-FAM-A2b11 solution, IL13RA2 antibody (Beyotime, China), and DAPI were sequentially applied for staining.

Techniques: Quantitative Proteomics, Expressing

Journal: Materials Today Bio

Article Title: Development and evaluation of IL13RA2 targeted drug delivery system based on glioblastoma homing peptide A2b11

doi: 10.1016/j.mtbio.2026.102823

Figure Lengend Snippet: Expression of IL13RA2 in Glioblastoma ( a ) IL13RA2 mRNA expression levels in normal brain tissues (n = 6), LGG tissues (n = 10), and HGG tissues (n = 10) detected by qRT-PCR (normalized to GAPDH, 2 ^(−ΔΔCT) method; ∗ P < 0.05 ). ( b ) RT-qPCR detection of IL13RA2 mRNA expression levels in three GBM cell lines and normal glial cells HEB, data are presented as the mean ± SD of three independent experiments. (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). ( c-d ) Western blot analysis of IL13RA2 protein expression (molecular weight ∼55 kDa; GAPDH [37 kDa] as internal control; quantitative analysis by ImageJ software, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001). ( e ) Immunofluorescence localization of IL13RA2 (red fluorescence) in cells (DAPI: blue, nuclear staining; laser confocal microscopy, non-permeabilized condition; scale bar = 50 μm; HEB cells show negligible IL13RA2 signal, while GBM cells exhibit strong membrane-localized fluorescence). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Subsequently, 5′-FAM-A2b11 solution, IL13RA2 antibody (Beyotime, China), and DAPI were sequentially applied for staining.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Molecular Weight, Control, Software, Immunofluorescence, Fluorescence, Staining, Confocal Microscopy, Membrane

Journal: Materials Today Bio

Article Title: Development and evaluation of IL13RA2 targeted drug delivery system based on glioblastoma homing peptide A2b11

doi: 10.1016/j.mtbio.2026.102823

Figure Lengend Snippet: In Vitro Binding of A2b11 Peptide to IL13RA2 Protein ( a ) Immunofluorescence colocalization analysis (A2b11 labeled with FAM: green fluorescence; IL13RA2 antibody: red fluorescence; DAPI: blue, nuclear staining; scale bar = 50 μm; Pearson's correlation coefficients: U251MG = 0.867 ± 0.015, U373MG = 0.920 ± 0.026, U87MG = 0.933 ± 0.015, mean ± SD, n = 3 independent experiments). ( b ) SPR sensorgram of IL13RA2 protein immobilization on CM5 chip (activation by EDC/NHS, deactivation by ethanolamine-HCl; immobilization level = 4558.8 RU). ( c ) SPR binding sensorgram of A2b11 peptide (analyte, concentration = 100 μM, sequence = WALRVKAG) with immobilized IL13RA2 (binding response = 12.7 RU; data analyzed by Biacore software). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Subsequently, 5′-FAM-A2b11 solution, IL13RA2 antibody (Beyotime, China), and DAPI were sequentially applied for staining.

Techniques: In Vitro, Binding Assay, Immunofluorescence, Labeling, Fluorescence, Staining, Activation Assay, Concentration Assay, Sequencing, Software

Journal: Acta neuropathologica communications

Article Title: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

doi: 10.1186/s40478-025-01991-4

Figure Lengend Snippet: Fig. 1 IL13RA2 shows heterogenous expression in human DIPG. (A) IL13RA2 gene expression in pediatric brain tumors from Gump database was ana lyzed using GlioVis (http://gliovis.bioinfo.cnio.es/). Tukey’s Honest Significant Difference (HSD) was performed to compare IL13RA2 gene expression be tween pediatric tumors. Significance was denoted in the graph by one asterisk (*) where p < 0.05, two (**) where p < 0.01, and three (***) where p < 0.001. (B) IL13RA2 histopathological scores of post-mortem patient samples. (C) Representative images of each IL13RA2 histopathological score in post-mortem human pDMG patient samples (top panel) and corresponding H&E stains (bottom panel). Each image includes high-power insets at low-power fields (top right hovering image)

Article Snippet: Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4 °C.

Techniques: Expressing, Gene Expression

Journal: Acta neuropathologica communications

Article Title: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

doi: 10.1186/s40478-025-01991-4

Figure Lengend Snippet: Fig. 2 Analysis of GEM models of midline glioma expressing IL13RA2. (A) Visual schematic of RCAS vector generated with PDGFB and IL13RA2 transgenes flanked by recombination att sites used to transfect DF-1 cells. Validation of PDGFB and IL13RA2 expression in DF-1 by (B) flow cytometry and (C) western blot. (D) Comparison of survival for Nestin-Tva; p53fl/fl mice injected at midline location with DF-1 producing virus containing RCAS-CRE and PDGFB or PDGFB + IL13RA2

Article Snippet: Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4 °C.

Techniques: Expressing, Plasmid Preparation, Generated, Biomarker Discovery, Flow Cytometry, Western Blot, Comparison, Injection, Virus

Journal: Acta neuropathologica communications

Article Title: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

doi: 10.1186/s40478-025-01991-4

Figure Lengend Snippet: Fig. 4 De novo PDGF-B/ IL13RA2 overexpressing tumors respond to CAR T-cell therapy. (A) Survival analysis of mice with de novo cortical tumor of Nestin- Tva; p53fl/fl/ PTEN fl/fl mice treated with saline (n = 8), non-transduced (NT) T-cells (n = 13) or CAR T-cells (n = 12), ***p < 0.0001. (B) H&E stain of mouse brain from control (left panel) and CAR T-cell-treated (right panel) long-term surviving mice. (C-H) Flow cytometric analysis of tumor microenvironment of nestin-Tva; p53fl/fl/ PTEN fl/fl mice treated with saline (white), non-transduced (NT) T-cells (blue) or CAR T-cells (red)

Article Snippet: Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4 °C.

Techniques: Saline, Staining, Control